
EBCC 2024
1 interview16 min
European Breast Cancer Conference
Interviews and expert commentary from EBCC 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.

Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC
28 August 2025
16 min